HCPCS Level II code S0187 denotes tamoxifen citrate, oral, 10 mg — a commonly used endocrine therapy in oncology for hormone receptor–positive cancers. Nationally, this code is used for billing the specific oral medication formulation and dosage, supporting consistent pharmacy and outpatient clinic reimbursement for tamoxifen maintenance and adjuvant therapy. Accurate coding of oral oncology agents is important for claims processing, benefit coordination, and patient cost-sharing calculations across commercial and public payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of how S0187 is categorized in claims, common sites of service where it is billed, and typical clinical contexts for tamoxifen use. The publication summarizes benchmarks and policy-relevant considerations affecting coverage and billing for oral oncologic agents, highlights where coding precision matters for pharmacy versus medical benefit adjudication, and outlines implications for reimbursement workflows.

Data not available in the input is noted where specific payer policies, associated taxonomies, ICD-10 pairings, and related codes are required for detailed billing guidance.